RNA N-6-methyladenosine enzymes and resistance of cancer cells to chemotherapy and radiotherapy.

Meiyi Xiang, Wensu Liu, Wei Tian, Abin You, Dajun Deng

Journal: Epigenomics 2021;12(9):801-809

PMID: 32515221

Abstract

As one of the early adaptive mechanisms by which cells respond to environmental changes, RNA modification appears to be a very promising target for cancer treatment. RNA modifications are currently a hot topic in epigenetic research. Emerging experimental studies show that expression alterations of multiple m6A enzymes, including demethylase FTO, methyltransferase METTL3 and WTAP, mediate the development of resistance of cancer cells to various treatments. A set of small molecular chemical drugs targeted to these m6A enzymes are under development. Intervention of RNA m6A methylation is a possible therapeutic strategy to overcome drug resistance. RNA m6A methylation may play a crucial role in drug resistance development and intervention in cancer cells.

Address: Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Division of Etiology, Peking University Cancer Hospital & Institute, Fu-Cheng-Lu #52, Haidian District, Beijing 100142, PR China.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.